Effects of CAPAH, memantine, and rivastigmine on behavioral and cognitive functions of rats

Relevance. Alzheimer’s disease (AD) is a neurodegenerative disease characterized by cognitive and behavioral disorders. The drugs currently used in clinical practice can slow drug development but are usually associated with lifelong use because of the complexity of pathogenesis. Therefore, to correct AD, a similar approach is needed, which can be CAPAH (2-chloroethoxy-para-N-dimethylaminophenylphosphorylacetohydrazide), a potential drug with a multitarget mechanism of action.

Objective. Investigate the effects of CAPAH, memantine, and rivastigmine on the behavior and cognitive functions of rats.

Materials and methods. This study identified CAPAH as a potential drug with a multitarget mechanism of action. The comparator drugs were memantine (10 mg/kg) and rivastigmine (2 mg/kg). Animals were divided into 4 groups (control, CAPAH, memantine, rivastigmine), 8 males and 9 females each receiving subcutaneous injections of the respective agents for 30 days. Subsequently, their cognitive functions and behavior were studied on the «Morris Water Maze» (MWM) and «Extrapolation deliverance» (EPI) ("Open Science", Russia) with the help of the "EthovisionXT" program (Noldus, the Netherlands). Statistical processing was performed using one-way ANOVA in the GraphPadPrism 8.0.1 program.

Results. In case “MWM” CAPAH increased the swimming time in the platform zone by 1.8 and 1.5 times (p < 0.05) compared with the control in the male and female groups, respectively, exceeding the parameters of the comparison drug. In case "EPI" test, the administration of CAPAH to males reduced the number of jumps by 4.4 times (p < 0.05) and increased the latent period of motor activity by 2.3 times (p < 0.05) compared with the control group, but did not affect these aspects in females.

Conclusion. Administration of CAPAH improves cognitive function and memory in healthy male and female rats and reduces anxiety in male rats, whereas it outperforms the effects of memantine and rivastigmine.

1. Kicherova OA, Reikhert LI. Alzheimer’s disease. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(1):77-81. (In Russ.). doi: 10.17116/jnevro20181181177-81.

2. Vasenina EE, Levin OS, Sonin AG. Modern trends in epidemiology of dementia and management of patients with cognitive impairment. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(6-2):87-95. (In Russ.). doi: 10.17116/jnevro20171176287-95.

3. Koberskaya NN. Alzheimer’s disease: new diagnostic criteria and therapeutic aspects depending on the stage of the disease. Meditsinskiy sovet. 2017;10:18-24. (In Russ.). doi: 10.21518/2079-701X-2017-10-18-24.

4. Sakharov AV, Mynduskin IV, Tereshkov PP. Indicators of neuro-repair in patients with the first episode of schizophrenia during antipsychotic therapy. Siberian Herald of Psychiatry and Addiction Psychiatry. 2020;4(109):15-20. (In Russ.). doi: 10.26617/1810-3111-2020-4(109)-15-20.

5. Tyuvina NA, Prokhorova SV, Maksimova TN, Verbitskaya MS. Cognitive impairments in depression and Alzheimer's disease: differential diagnosis and approaches to therapy. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):116-123. (In Russ.). doi: 10.14412/2074-2711-2019-3-116-123.

6. Ponomareva EV. Depressive disorders in Alzheimer's disease. Psikhiatriya. 2008;4(6):85-91. (In Russ.).

7. Ponomaryova EV. Depression in Alzheimer's disease. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(2):4-11. (In Russ.).

8. Levin OS, Lyashenko EA. Anxiety and comorbid conditions. Nervous diseases. 2016;(1):28-34. (In Russ.).

9. Grigorenko AP, Rogaev EI. Molecular basics of alzheimer's disease. Molekulyarnaya biologiya. 2007;41(2):331-345. (In Russ.).

10. Naumenko AA, Preobrazhenskaya IS. Patogenez, diagnostika i terapiya bolezni Al'cgejmera. Meditsinskiy sovet. 2015;(5):46-54. (In Russ.). doi: 10.21518/2079-701X-2015-5-46-54.

11. Lobzin VYu, Kolmakova KA, Emelin AYu. A novel view on Alzheimer’s disease pathogenesis: modern concept of amyloid clearance. V.M. Bekhterev review of psychiatry and medical psychology. 2018;(2):22-28. (In Russ.). doi: 10.31363/2313-7053-2018-2-22-28.

12. Polunina AG, Bryun EA. Episodic memory: neurological and neuromediator mechanisms. Annals of Clinical and Experimental Neurology. 2012;6(3):53-60. (In Russ.).

13. Shmakova AA, Androsova LV. Modeling Alzheimer’s disease in animals. Psikhiatriya. 2018;1(77):97-108. (In Russ.). doi: 2618-6667-2018-77-97-108.

14. Mankovsky NB, Kuznetsova SM. Age-related changes in brain neurotransmitter systems as a risk factor for cerebrovascular pathology. The Journal of Neuroscience. 2013;1(2):5-13. (In Russ.).

15. Vasenina EE, Levin OS. The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease. Neurology, Neuropsychiatry, Psychosomatics. 2012;(3):96-99. (In Russ.).

16. Lemina EY, Churyukanov VV. Anticholinesterase agents: current evaluation. Experimental and clinical pharmacology. 2019;82(5):40- 44. (In Russ.). doi: 10.30906/0869-2092-2019-82-5-40-44.

17. Tyuvina NA, Balabanova VV. Treatment for Alzheimer's diseases. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(3):80-85. (In Russ.). doi: 10.14412/2074-2711-2015-3-80-85.

18. Damulin IV. Rivastigmine in the treatment of dementia: from the symptomatic effect to neuroprotection. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2010; 110(9):76-82. (In Russ.).

19. Kolykhalov IV. Treatment of behavioral and psychotic symptoms of Alzheimer's disease: the contribution of memantine. Modern therapy in psychiatry and neurology. 2013;3(4):17-20. (In Russ.).

20. Folch J, Busquets O, Ettcheto M, et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J Alzheimers Dis. 2018;62(3):1223-1240. doi: 10.3233/JAD-170672.

21. Gavrilova SI. Memantine in treatment of Alzheimer’s disease: 20 years of clinical use. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6-2):10-18. (In Russ.). doi: 10.17116/jnevro20161166210-18.

22. Науменко А.А., Преображенская И.С. Патогенез, диагностика и терапия болезни Альцгеймера. Медицинский совет. 2015;(5):46-54. [Naumenko AA, Preobrazhenskaya IS. Pathogenesis, diagnosis and treatment of Alzheimer's disease. Meditsinskiy sovet. 2015;(5):46-54. (In Russ.).

23. Henry BL, Minassian A, Young JW, et al. Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev. 2010 Jul;34(8):1296-306. doi: 10.1016/j.neubiorev.2010.04.002.

24. Semina II, Shilovskaya EV, Tarasova RI, et al. Mekhanizmy psihotropnogo dejstviya gidrazidov fosforilirovannyh karbonovyh kislot. Khimiko-Farmatsevticheskii Zhurnal. 2002;36(4):3-6. (In Russ.). doi: 10.30906/0023-1134-2002-36-4-3-6.

25. Nikitina AV, Semina II, Baychurina AZ, et al. New derivatives of phosphorus-containing compounds with amino acid and triazolethione fragments are potential drugs that improve memory and cognitive functions. Kazan medical journal. 2023;104(1):72-80. (In Russ.). doi: 10.17816/KMJ108603.

26. Semina II, Baychurina AZ, Shilovskaya EV, et al. Study of metabolic disorders in rats under exposure to hypobaric hypoxia and development of-correction approaches by simultaneous action on different elements of pathogenesis. Kazan medical journal. 2021;102(5):654-662. (In Russ.). doi: 10.17816/KMJ2021-654.

27. Semina II, Baychurina AZ. Development of new potential drugs with psychotropic activity among phosphorylacetohydrazides and other phosphorylated carboxylic acids derivatives — priority area of Kazan school of psychopharmacologists. Kazan medical journal. 2016;97(1):148-155. (In Russ.). doi: 10.17750/KMJ2016-148.

28. Kolobov VV, Storozheva ZI. Modern pharmacological models of Alzheimer's disease. Annals of Clinical and Experimental Neurology. 2014;8(3):38-44. (In Russ.). doi: 10.17816/psaic173.

29. Mironov AN, Bunyatyan ND, Vasiliev AN, et al. Guidelines for conducting preclinical studies of drugs. Part 1 / Ed by AN Mironova. Moscow: Grif i K; 2012. (In Russ.).

30. Svensson M, Hallin T, Broms J, et al. Spatial memory impairment in Morris water maze after electroconvulsive seizures. Acta Neuropsychiatr. 2017 Feb;29(1):17-26. doi: 10.1017/neu.2016.22.

31. Ivlieva AL, Petritskaya EN, Rogatkin DA, Demin VA. Methodological Characteristics of the Use of the Morris Water Maze for Assessment of Cognitive Functions in Animals. Neuroscience and Behavioral Physiology. 2017;47(4):484-493. (In Russ.). doi: 10.1007/s11055-017-0425-z.

32. Yakimova NL, Sosedova LM. Dophamine-dependent disorder of conduct of albino rats with sublimate intoxication in the test of extrapolation deliverance. Acta Biomedica Scientifica. 2013;1(89):130-133. (In Russ.).

33. Sabatos-DeVito M, Murias M, Dawson G, et al. Methodological considerations in the use of Noldus EthoVision XT video tracking of children with autism in multi-site studies. Biol Psychol. 2019 Sep;146:107712. doi: 10.1016/j.biopsycho.2019.05.012.